Trimodality therapy may improve mesothelioma patient outcomes

23 Aug 2017 by Sarah Mahan under Research/Treatment

598px Chemotherapy vials 3 100x100 Trimodality therapy may improve mesothelioma patient outcomesMalignant is an aggressive cancer, rarely responding to a single form of treatment, and the cancer’s tenacity has researchers constantly searching for combinations of therapies that improve patient outcomes. A recent study at MD Anderson Cancer Center supports the use of trimodality therapy, specifically cancer-directed surgery, chemotherapy and radiation, in improving patient outcomes.

The researchers narrowed down a pool of 20,561 pleural mesothelioma patients diagnosed between 2004 and 2014 to 6,645 patients who were carefully matched for their similar characteristics, according to Surviving . “Of these, 850 underwent surgery, 988 had surgery with chemotherapy, and 274 underwent trimodality therapy,” according to the news source. They then compared the patients’ outcomes and determined trimodality therapy was associated with improved survival rates.

“Stratified analysis revealed that surgery-based multimodality therapy demonstrated an improved survival compared with surgery alone, with no significant difference between surgery-based and multimodality therapies; however, the largest estimated effect was when cancer-directed surgery, chemotherapy, and radiation therapy were combined,” the study states.

For patients with epithelioid pleural mesothelioma, the most common subtype of the cancer that affects the lining of the lungs, trimodality therapy extended their survival from 14.5 months to 23.4 months. Typically, patients rarely live more than a year after diagnosis.

“Surgery-based multimodality therapy was associated with improved survival and may offer therapeutic benefit among carefully selected patients,” the study concluded.

is caused by exposure to asbestos, a group of six silicate minerals that were once used in a variety of construction and manufacturing processes for its heat resistance and flexibility. It is now known to cause cancer and is banned in many countries, including in the European Union.

 

Comments are closed.